Lipoprotein(a) — Lp(a)
An LDL-like particle with an added apolipoprotein(a) tail. Your level is roughly 90% genetically determined and essentially fixed for life.
An independent, causal risk factor for heart attack, stroke and aortic stenosis that almost nobody tests. Because it's genetic and stable, it only needs to be measured once in a lifetime — and every current guideline says to do exactly that.
The plan of attack
In this order. Most people start at step four, which is why they change five things at once and learn nothing.
- Confirm the number is real
Units — mg/dL vs nmol/L. Not a biological interference but the most common misreading of this marker. The two units are not interchangeable and there is no exact conversion, because the assay depends on particle size. Use nmol/L where possible, and never compare a mg/dL result to an nmol/L threshold. - Read it with its partner
Test once, ever. If elevated, it permanently reframes how hard you should treat ApoB and blood pressure — one of the highest-value single tests in all of medicine, and it costs $25. Draw it alongside: ApoB (Apolipoprotein B), Lipid Panel (Cholesterol, HDL, LDL, Triglycerides), hs-CRP (High-Sensitivity C-Reactive Protein). - Work out which direction is yours
If it's high — Means every other risk factor — ApoB, blood pressure, insulin resistance, smoking — must be controlled more aggressively, because your baseline risk is already elevated. It also strengthens the case for early imaging (coronary calcium score). - Fix it in this order
Nutrition. Diet barely moves Lp(a) — and that's not a failure, it's the biology. Don't chase it with food; control ApoB instead.
Lifestyle. Since you can't lower it much, the play is aggressively managing everything you can control — blood pressure, ApoB, glucose, smoking, fitness.
Supplements. Niacin lowers it modestly (~20%) but hasn't shown outcome benefit and has side effects. No supplement meaningfully helps.
Hormones. PCSK9 inhibitors lower Lp(a) ~25%. Targeted RNA therapies (pelacarsen, olpasiran) are in phase 3 and may change this entirely. Estrogen therapy lowers it in postmenopausal women.
Compounds. No peptide interaction. Purely a risk-stratification test.
Work down the list, not across it. Adding a compound on top of an unfixed diet is why generic protocols fail. - Retest
Once in a lifetime is sufficient unless kidney or thyroid status changes markedly. Change one thing at a time, or the retest can't tell you which thing worked.
How to fix it
📚 2026 AHA/ACC Dyslipidemia Guideline — measure at least once. Tsimikas S, J Am Coll Cardiol 2017 — Lp(a) as a causal risk factor.
🩸 Test your Lipoprotein(a) — Lp(a)
Order directly through Marek Diagnostics — no doctor's visit needed, drawn at any Quest location in the US. Code CAMERON applies 10% off automatically.
Order this test — 10% off → Browse all 102 markers →What Lipoprotein(a) — Lp(a) is usually tested alongside
On its own, one marker is a data point. These panels include Lipoprotein(a) — Lp(a) plus the markers that make it interpretable — each names every test, why it is on the list, and loads the whole set into your cart in one click at 10% off.
includes this + 8 more markers — Anyone over 30, anyone with a family history of early heart disease, or anyone who's been told their cholesterol is 'fine' and wants to know what that actually means.
includes this + 8 more markers — Family history of clots, stroke or early heart attack; on testosterone or oestrogen; long-haul travel; or a standard lipid panel that looked fine and you don't believe it.
includes this + 10 more markers · built for women — Anywhere from late 30s onward with cycle changes, night sweats, sleep disruption, mood shifts, joint aches, brain fog, or a libido that fell off a cliff.
Would you feel it? Symptoms Lipoprotein(a) — Lp(a) helps explain
People rarely search for a marker — they search for how they feel. These are the complaints where this marker is worth checking, and whether it is a first-line test or a follow-up once the obvious causes are ruled out.
Why your Lipoprotein(a) — Lp(a) might be wrong
Most abnormal results are interference, not disease. These are the things that measurably move this specific marker — check them before you change anything. Each one says whether the number is wrong and should be repeated, badly timed and should be redrawn, or real with a cause worth explaining.
Lp(a) is a modest acute-phase reactant and rises during inflammation, which is the main reason a repeat value differs from the first.
Measure when well. And you only need it once — it is genetically fixed.
Not a biological interference but the most common misreading of this marker. The two units are not interchangeable and there is no exact conversion, because the assay depends on particle size.
Use nmol/L where possible, and never compare a mg/dL result to an nmol/L threshold.
What Lipoprotein(a) — Lp(a) means in combination
A single marker tells you a little. Combinations tell you the story — these are the named patterns this marker takes part in, and what each one points at.
Lp(a) is almost entirely genetic, largely unmoved by diet, and independently raises cardiovascular and aortic valve risk. A normal LDL alongside it is falsely reassuring.
Measure it once — it barely changes over a lifetime. You cannot lower it much yet, so the response is to drive everything else down hard: ApoB, blood pressure, insulin resistance, smoking. Tell your first-degree relatives to test theirs.
Several independent contributors to clot risk stacking together. Each is unremarkable alone; the combination is not, particularly alongside androgen use, high haematocrit, oestrogen therapy or long-haul travel.
A raised D-dimer with leg swelling, chest pain or breathlessness is an emergency, not a retest. Otherwise: address homocysteine with B12/folate/B6, treat the inflammation driving fibrinogen, and review anything oestrogenic or androgenic you are taking with a clinician.
What to test next
Markers rarely answer alone. These are the ones that put Lipoprotein(a) — Lp(a) in context — each with its own full breakdown.
Frequently asked questions
<75 nmol/L (or <30 mg/dL) reported as normal — risk is continuous Ranges vary by laboratory and assay — always compare to the range printed on your own report.
<75 nmol/L desirable. ≥125 nmol/L (~50 mg/dL) is a recognized risk-enhancing threshold (~1.4× ASCVD risk); 300–400 nmol/L approaches heterozygous familial hypercholesterolemia risk.
Means every other risk factor — ApoB, blood pressure, insulin resistance, smoking — must be controlled more aggressively, because your baseline risk is already elevated. It also strengthens the case for early imaging (coronary calcium score).
Favorable; nothing to act on.
You can order Lipoprotein(a) — Lp(a) directly through Marek Diagnostics without a doctor's visit — drawn at any Quest Diagnostics location in the US. Code CAMERON applies 10% off automatically.